You're contacting media contact of this press release

Title: CRISPR Advances Drive Biomedical Innovation in the United States

Advancing Genetic Research and Supporting U.S. Leadership in Biomedical InnovationIn the evolving landscape of American biomedical innovation, one emerging scientist is helping redefine how the nation approaches neurodegenerative disease treatment. Drawing on the power of CRISPR-based genetic engineering, Xin-Yu Wen’s research seeks to illuminate the molecular mechanisms driving Alzheimer’s and Parkinson’s disease — two of the most urgent public health challenges in an aging United States. By bridging laboratory discovery with clinical application, her work embodies the growing convergence between precision gene editing and neurological medicine, offering not only new hope for patients but also advancing America’s strategic leadership in biotechnology and public health.Across the country, more than six million Americans live with Alzheimer’s disease, while Parkinson’s affects nearly one million more. These conditions not only impose emotional hardship but also place an economic burden exceeding several hundred billion dollars annually. For decades, most interventions have focused on symptom management rather than prevention or reversal. Wen’s approach diverges sharply from this tradition. Through gene editing and molecular analysis, her research targets the fundamental genetic pathways that drive neurodegeneration. The goal is to shift the focus of neuromedicine from reactive care to proactive genetic intervention—a transformation with the potential to redefine how the United States addresses aging-related diseases.Wen’s scientific foundation was established at the University of California, San Diego, where she pursued dual undergraduate degrees in biochemistry and psychology. This interdisciplinary training gave her an uncommon ability to connect molecular biology with...

This press release is issued by King Newswire